Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

181. [Baricitinib (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V]

[Baricitinib (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V] Baricitinib (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-14 [Baricitinib (rheumatoid arthritis) - benefit assessment according to §35a Social Code Book V] Baricitinib (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-14 [Baricitinib (rheumatoid arthritis) - benefit assessment according to §35a Social Code Book V (...) ] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Baricitinib (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-14. [Baricitinib (rheumatoid arthritis) - benefit assessment

2017 Health Technology Assessment (HTA) Database.

182. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study Full Text available with Trip Pro

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX).In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once daily (n=487), or adalimumab 40 mg biweekly (n=330 (...) ) with background MTX. PROs included the SF-36, EuroQol 5-D (EQ-5D) index scores and visual analogue scale, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis (WPAI-RA), and measures collected in electronic patient daily diaries: duration and severity of morning joint

2017 EvidenceUpdates

183. Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry Full Text available with Trip Pro

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry Current recommendations for the management of rheumatoid arthritis (RA) focus on a treat-to-target approach with the objective of maximizing long-term health-related quality-of-life in patients with RA. Published studies from randomized clinical trials have reported limited data regarding the long-term efficacy and safety of adalimumab in patients

2017 Rheumatology and therapy

184. Treatment with Biologicals in Rheumatoid Arthritis: An Overview Full Text available with Trip Pro

Treatment with Biologicals in Rheumatoid Arthritis: An Overview Management and therapy of rheumatoid arthritis (RA) has been revolutionized by the development and approval of the first biological disease-modifying antirheumatic drugs (bDMARDs) targeting tumor necrosis factor (TNF) α at the end of the last century. Today, numerous efficacious agents with different modes of action are available and achievement of clinical remission or, at least, low disease activity is the target of therapy

2017 Rheumatology and therapy

185. Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry Full Text available with Trip Pro

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry Despite the availability of multiple effective therapies, discontinuation/switching of treatment is common for many patients with rheumatoid arthritis (RA). This study was designed to examine initiation of biologic disease-modifying anti-rheumatic drugs (bDMARDs) within the Consortium of Rheumatology Researchers of North America (Corrona) RA Registry, and characterize reasons

2017 Rheumatology and therapy

186. Switching From Immediate-Release to Delayed-Release Prednisone in Moderate to Severe Rheumatoid Arthritis: A Practice-Based Clinical Study Full Text available with Trip Pro

Switching From Immediate-Release to Delayed-Release Prednisone in Moderate to Severe Rheumatoid Arthritis: A Practice-Based Clinical Study Rheumatoid arthritis (RA) produces debilitating morning stiffness. Exogenous glucocorticoids can help with these symptoms when timed appropriately. Bedtime dosing of delayed-release prednisone (DR-prednisone) matches the rise of inflammatory cytokines before awakening and can improve stiffness and other RA symptoms. A prospective open-label study

2017 Rheumatology and therapy

187. Identification and Treatment Optimization of Comorbid Depression in Rheumatoid Arthritis Full Text available with Trip Pro

Identification and Treatment Optimization of Comorbid Depression in Rheumatoid Arthritis Patients with rheumatoid arthritis (RA) suffer from high rates of depression but depression often remains undiagnosed and untreated among RA patients. Because of its high prevalence and its profound impact on functional disability and health-related quality of life, prompt recognition and management of comorbid depression is urgently needed in patients with RA. Rheumatologists face the challenge

2017 Rheumatology and therapy

188. Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis Full Text available with Trip Pro

Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis Lung disease is one of the most common causes of extra-articular morbidity and mortality in patients with rheumatoid arthritis (RA). Development of pulmonary manifestations may be due to the systemic disease itself; to serious respiratory adverse events such as pneumonitis and infections secondary to therapy; or to lifestyle habits such as smoking. Rheumatologists often need to make important treatment

2017 Rheumatology and therapy

189. Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks (Abstract)

Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks Acute coronary syndrome (ACS) and other cardiovascular diseases are the main drivers of the increased morbidity and preterm mortality in rheumatoid arthritis (RA). ACS in RA has been linked to inflammation and RA severity. During recent years and with new therapeutic options and treat-to-target strategies, increasing efforts have been made to reach RA

2017 EvidenceUpdates

190. Baricitinib for moderate to severe rheumatoid arthritis

Baricitinib for moderate to severe rheumatoid arthritis Baricitinib for moder Baricitinib for moderate to se ate to sev vere ere rheumatoid arthritis rheumatoid arthritis T echnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Baricitinib for moderate to severe rheumatoid arthritis (TA466) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 23Contents Contents 1 Recommendations 4 2 The technology 6 3 Committee discussion 7

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

191. The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms Full Text available with Trip Pro

The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms Even after achieving tremendous advances in diagnosis and treatment of rheumatoid arthritis (RA), many of the patients undergo delays in diagnosis and initiation of treatment, which leads to worsening of the condition and poor prognosis.The objective of this study was to perform a literature review to quantify the lag times in diagnosis and treatment of RA and study the reported factors

2017 Open access rheumatology : research and reviews

192. Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis Full Text available with Trip Pro

Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis Cardiovascular (CV) comorbidities are a frequent extra-articular manifestation of rheumatoid arthritis (RA). Cardiovascular disease (CVD) with accelerated atherosclerosis is a major cause of morbidity and mortality in patients with RA. Subclinical CVD may be present since the early phase of RA. Not only traditional but also non-traditional CV risk factors are involved in the pathogenesis of RA-related CVD. Due

2017 Rheumatology and therapy

193. Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action Full Text available with Trip Pro

Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action Many types of treatment are available for patients with rheumatoid arthritis (RA), however, some patients fail to achieve remission. This report aims to determine the safety and efficacy of using repository corticotropin injection (RCI) as an adjunctive therapy in patients with RA refractory to at least three therapeutics

2017 Open access rheumatology : research and reviews

194. The Effect Size of Fibromyalgia on PG-VAS in Rheumatoid Arthritis Patients. Adjustment Proposal in DAS28-ESR: Letter to the Editor regarding Challa, D.N.V., Crowson, C.S. & Davis, J.M. Rheumatol Ther (2017) 4: 201. doi:10.1007/s40744-017-0063-5 Full Text available with Trip Pro

The Effect Size of Fibromyalgia on PG-VAS in Rheumatoid Arthritis Patients. Adjustment Proposal in DAS28-ESR: Letter to the Editor regarding Challa, D.N.V., Crowson, C.S. & Davis, J.M. Rheumatol Ther (2017) 4: 201. doi:10.1007/s40744-017-0063-5 28685293 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther The Effect Size of Fibromyalgia on PG-VAS in Rheumatoid Arthritis Patients. Adjustment Proposal in DAS28-ESR: Letter to the Editor regarding Challa, D.N.V., Crowson, C.S (...) Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Avenida Gonzalitos 235 Norte, Monterrey, Nuevo León, México. Esquivel-Valerio Jorge Antonio JA Servicio de Reumatología, Departamento de Medicina Interna, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Avenida Gonzalitos 235 Norte, Monterrey, Nuevo León, México. eng Letter 2017 07 06 England Rheumatol Ther 101674543 2198-6576 Fibromyalgia Rheumatoid arthritis 2017 05 28 2017 7 8 6 0

2017 Rheumatology and therapy

195. Tropical pyomyositis caused by Klebsiella pneumoniae with rheumatoid arthritis Full Text available with Trip Pro

Tropical pyomyositis caused by Klebsiella pneumoniae with rheumatoid arthritis 29657883 2018 11 30 2147-9720 5 1 2018 Mar European journal of rheumatology Eur J Rheumatol Tropical pyomyositis caused by Klebsiella pneumoniae with rheumatoid arthritis. 83-84 10.5152/eurjrheum.2017.160126 Carneiro Juliana Brandão Pinto JBP http://orcid.org/0000-0001-7184-0582 Department of Rheumatology, Getúlio Vargas University Hospital (HUGV), Federal University of Amazon School of Medicine (UFAM), Manaus

2017 European journal of rheumatology

196. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality (Abstract)

A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality To compare mortality risks in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and patients with RA without ILD.Matched cohort study.The study was conducted in Denmark, using nationwide, prospectively collected data.Among patients with RA diagnosed between 2004 and 2016, 679 patients with RA-ILD were matched for birth year, gender and age at RA

2017 EvidenceUpdates

197. Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis Full Text available with Trip Pro

Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis To assess the diagnostic value of MRI for early RA. In some RA patients, a classifiable diagnosis cannot be made at first presentation; these patients present with unclassified arthritis (UA). The use of MRI for early diagnosis of RA is recommended, yet the evidence for its reliability is limited.MRI of hand and foot was performed in 589 early arthritis patients included in the Leiden Early Arthritis

2017 EvidenceUpdates

198. Etanercept (Erelzi) - rheumatoid arthritis, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis

Etanercept (Erelzi) - rheumatoid arthritis, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 21 April 2017 EMA (...) Kilogram MAA Marketing Authorisation Application mg Milligram MMRM Mixed Model Repeated Measure N Na ns Number of Patients Not analysed Not specified PASI Psoriasis Area and Severity Index PC Placebo-controlled PD Pharmacodynamics PK Pharmacokinetics PPS Per-protocol set RA Rheumatoid arthritis SAE Serious Adverse Event SAP Statistical Analysis Plan SD SDV Standard deviation Source Data Verification SmPC Summary of Product Characteristics sTNF soluble Tumour Necrosis Factor TEAE Treatment-emergent

2017 European Medicines Agency - EPARs

199. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial (Abstract)

Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial Tumour necrosis factor inhibitors (TNFi) are effective in rheumatoid arthritis (RA), but disadvantages include adverse events (AEs) and high costs. This can be improved by disease activity-guided dose reduction (DR). We aimed to assess long-term outcomes of TNFi DR in RA by using 3-year data

2017 EvidenceUpdates

200. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study Full Text available with Trip Pro

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study ABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that the two are highly similar. We report results from a phase III study comparing efficacy, safety and immunogenicity between ABP 501 and adalimumab.In this randomised (...) , double-blind, active comparator-controlled, 26-week equivalence study, patients with moderate to severe active rheumatoid arthritis (RA) despite methotrexate were randomised (1:1) to ABP 501 or adalimumab (40 mg) every 2 weeks. Primary endpoint was risk ratio (RR) of ACR20 between groups at week 24. Primary hypothesis that the treatments were equivalent would be confirmed if the 90% CI for RR of ACR20 at week 24 fell between 0.738 and 1.355, demonstrating that ABP 501 is similar to adalimumab

2017 EvidenceUpdates